THE EFFECT OF DEXAMETHASONE TREATMENT ON MATERNAL OUTCOME IN HELLP SYNDROME

Thepatients receiving dexamethasone treatment showed an increasedimprovement in platelet count; however the difference was notstatistically significant.CONCLUSIONS: Dexamethasone treatment did not result in anyimprovement in mortality, length of ICU stay, and in the plateletcounts in patients with HELLP syndrome.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:INTRODUCTION: There are still controversies in the literatureregarding the role of corticosteroids in the treatment of HELLPsyndrome.

📊

Key Findings & Data:The aim of this study is to investigate the effect ofdexamethasone treatment on maternal outcome.MATERIALS AND METHODS: The study included 20 patientswho were followed in ICU with the diagnosis of HELLP syndrome.Data regarding the age, gestational age, Mississippi class, APACHEII score, hematologic and biochemical measurements, mortality andlength of ICU stay were analyzed retrospectively.RESULTS: Two patients died due to the multiple organ failure.Twelve patient received dexamethasone treatment (Group 1) andeight patients did not receive steroid treatment (Group 2).

💡

Conclusion & Impact:Thepatients receiving dexamethasone treatment showed an increasedimprovement in platelet count; however the difference was notstatistically significant.CONCLUSIONS: Dexamethasone treatment did not result in anyimprovement in mortality, length of ICU stay, and in the plateletcounts in patients with HELLP syndrome.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: There are still controversies in the literatureregarding the role of corticosteroids in the treatment of HELLPsyndrome. The aim of this study is to investigate the effect ofdexamethasone treatment on maternal outcome.MATERIALS AND METHODS: The study included 20 patientswho were followed in ICU with the diagnosis of HELLP syndrome.Data regarding the age, gestational age, Mississippi class, APACHEII score, hematologic and biochemical measurements, mortality andlength of ICU stay were analyzed retrospectively.RESULTS: Two patients died due to the multiple organ failure.Twelve patient received dexamethasone treatment (Group 1) andeight patients did not receive steroid treatment (Group 2). There wasnot any statistically significant difference in the length of ICU stay,mortality, and transfusion requirements between the groups. Thepatients receiving dexamethasone treatment showed an increasedimprovement in platelet count; however the difference was notstatistically significant.CONCLUSIONS: Dexamethasone treatment did not result in anyimprovement in mortality, length of ICU stay, and in the plateletcounts in patients with HELLP syndrome.

Özet

AMAÇ: Literatürde HELLP sendromunun tedavisinde kortikosteroid kullanımı ile ilgili çelişkili bilgiler bulunmaktadır. Bu çalışmanın amacı deksametazon tedavisinin maternal sonuçlar üzerindeki etkisinin araştırılmasıdır. YÖNTEMLER: Çalışmaya HELLP sendromu tanısı ile yoğun bakım ünitesinde izlenen 20 hasta dahil edilmiştir. Hasta yaşı, gestasyonel yaş, Mississipi sınflandırması, APACHE II skoru, hematolojik ve biyokimyasal ölçümler, mortalite ve yoğun bakım yatış günü gibi parametreler analiz edilmiştir. BULGULAR: Hastalardan ikisi çoklu organ yetmezliğine bağlı olarak ölmüştür. On iki hastaya deksametazon tedavisi verilmiş (Grup 1), 8 hasta ise kortikosteroid tedavisi almamıştır. Gruplar arasında yoğun bakım yatış süresi, transfüzyon gereksinimi ve mortalite açısından anamlı fark saptanmamıştır. Deksametazon tedavisi verilen grupta trombosit sayılarında artış daha fazla gerçekleşmiştir ancak bu artış istatistiksel fark yaratacak düzeyde olmamıştır. SONUÇ: HELLP sendromu tedavisinde dekzametazon kullanımı mortalite, yoğun bakım yatış günü ve trombosit sayılarında anlamlı bir fark yaratmamaktadır.

🔖

Cite This Article

TETİKER, S., ÇETİNALP, S., ÖZDOĞAN, H. K., SEYFETTİNOĞLU, S., NARİN, R., KARATEKE, F. (2022). THE EFFECT OF DEXAMETHASONE TREATMENT ON MATERNAL OUTCOME IN HELLP SYNDROME. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 52 - Sayı: 1, 8–12. https://ajindex.com/articles/441268

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (15)

)Geary M. The HELLP syndrome. Br J Obstet Gynaecol 1997
)Sibai BM, Taslimi MM, el-Nazer A, Amon E, Mabie BC, Ryan GM. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986
155(3): 501-9. 3.)Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990
)Benedetto C, Marozio L, Tancredi A, Picardo E, Nardolillo P, Tavella AM, Salton L. Biochemistry of HELLP syndrome. Adv Clin Chem 2011
)Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013
123 6.)Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: Clinical issues and management. A Review. BMC Pregnancy and Childbirth 2009
8 doi:10.1186/1471-2393-9-8 7.)Hemant K, Chabi S, Frey D. Hellp syndrome. J Obstet Gynecol India 2009
40 8.)Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006
)Martin JN Jr, Thigpen BD, Rose CH, Cushman J, Moore A, May WL. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003
)O'Brien JM1, Shumate SA, Satchwell SL, Milligan DA, Barton JR. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol 2002
)Yang L, Ren C, Mao M, Cui S. Prognostic Factors of the Efficacy of High-dose Corticosteroid Therapy in Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome During Pregnancy: A Meta-analysis. Medicine (Baltimore). 2016
95(13):e3203. 12.)Mao M, Chen C. Corticosteroid Therapy for Management of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count (HELLP) Syndrome: A Meta-Analysis. Med Sci Monit. 2015 Dec 3
)Noel ML, Brady CW. Liver disease in pregnancy. World J Gastroenterol 2009
906 14.)Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes and low platelet count. Obstet Gynecol 2004
)Fonseca JE, Mendez F, Catano C, Arias F. Dexamethasone treatment d